Brief: Palatin Technologies Says First Patient Enrolls In Phase 2 Study Of PL8177 For Ulcerative Colitis
20/10/2022 14:02
Oct 20 (Reuters) - Palatin Technologies Inc PTN.A :
* FIRST PATIENT ENROLLED IN PALATIN'S PHASE 2 STUDY OF
PL8177 IN
ULCERATIVE COLITIS TRIAL
Source text for Eikon: ID:nPn2Jjt5Ka
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity